title: Pancreatic cancer: BRCA mutation and personalized treatment.
abstract: The highly heterozygous nature of pancreatic cancer is partially responsible for its therapeutic ineffectiveness and resistance. Therefore, the ability to identify subgroups of pancreatic cancer with unique biological characteristics and treatment response is urgently needed. In addition to breast and ovarian cancer, pancreatic cancer is the third most common cancer type that is related to the early onset (BRCA) gene mutation in breast cancer. Mounting evidence has demonstrated that BRCA1/2-mutant breast and ovarian cancers are highly sensitive to DNA damage-related treatment, including poly(ADP-ribose) polymerase inhibitors (PARPi) and platinum-based agents. Preliminary evidence also showed promising results for DNA damage-related treatment in BRCA1/2-mutant pancreatic cancer. Importantly, several prospective clinical trials of PARPi-based regimens are underway for BRCA1/2-mutated pancreatic cancer. Pancreatic cancer with a BRCA1/2 mutation is a small subgroup with a promising therapeutic strategy.
authors.forename: Guopei
authors.initials: G
authors.lastname: Luo
authors.forename: Yu
authors.initials: Y
authors.lastname: Lu
authors.forename: Kaizhou
authors.initials: K
authors.lastname: Jin
authors.forename: He
authors.initials: H
authors.lastname: Cheng
authors.forename: Meng
authors.initials: M
authors.lastname: Guo
authors.forename: Zuqiang
authors.initials: Z
authors.lastname: Liu
authors.forename: Jiang
authors.initials: J
authors.lastname: Long
authors.forename: Chen
authors.initials: C
authors.lastname: Liu
authors.forename: Quanxing
authors.initials: Q
authors.lastname: Ni
authors.forename: Xianjun
authors.initials: X
authors.lastname: Yu
mesh_terms: D000970:Antineoplastic Agents; D019313:BRCA1 Protein / Q000235:genetics*; D024682:BRCA2 Protein / Q000235:genetics*; D004249:DNA Damage / Q000187:drug effects; D019008:Drug Resistance, Neoplasm; D006801:Humans; D009154:Mutation; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D057285:Precision Medicine
chemical_list: D000970:Antineoplastic Agents; D019313:BRCA1 Protein; C492913:BRCA1 protein, human; D024682:BRCA2 Protein; C551750:BRCA2 protein, human
keywords: BRCA1; BRCA2; personalized therapy; platinum; poly(ADP-ribose) polymerase inhibitors